Monahan J B, Biesterfeldt J P, Hood W F, Compton R P, Cordi A A, Vazquez M I, Lanthorn T H, Wood P L
Central Nervous System Diseases Research, G.D. Searle & Co., St. Louis, Missouri 63198.
Mol Pharmacol. 1990 Jun;37(6):780-4.
The competitive N-methyl-D-aspartate (NMDA) receptor antagonist D-2-amino-5-phosphonopentanoate and two other five-atom linkage (C-5) omega-phosphono-alpha-amino acid analogs reduced [3H]glycine binding, in a dose-dependent manner, to a maximum of 45-55%, whereas seven-atom linkage (C-7) analogs had significantly less effect. The IC50 of the C-5 antagonists for the inhibition of [3H]glycine binding closely paralleled their potency both in displacing NMDA-selective L-[3H]glutamate binding and in negatively modulating (+)-[3H]5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imi ne maleate ([3H]MK-801) binding. Additionally, reduction of glycine binding by the C-5 antagonists was reversed by both NMDA receptor agonists and C-7 competitive NMDA antagonists, providing evidence that the site of action of these C-5 antagonists is the NMDA recognition site, resulting in indirect modulation of the glycine site. These data imply a functional coupling between the NMDA and associated glycine recognition sites and, furthermore, suggest a differential interaction of C-5 and C-7 competitive NMDA antagonists with the NMDA receptor complex.
竞争性N-甲基-D-天冬氨酸(NMDA)受体拮抗剂D-2-氨基-5-膦酰基戊酸及其他两种五原子连接(C-5)的ω-膦酰基-α-氨基酸类似物以剂量依赖的方式使[3H]甘氨酸结合减少,最大减少至45%-55%,而七原子连接(C-7)类似物的作用则明显较小。C-5拮抗剂抑制[3H]甘氨酸结合的IC50与其在取代NMDA选择性L-[3H]谷氨酸结合以及负向调节(+)-[3H]5-甲基-10,11-二氢-5H-二苯并[a,d]环庚烯-5,10-亚胺马来酸盐([3H]MK-801)结合方面的效力密切平行。此外,NMDA受体激动剂和C-7竞争性NMDA拮抗剂均可逆转C-5拮抗剂对甘氨酸结合的减少,这表明这些C-5拮抗剂的作用位点是NMDA识别位点,从而导致对甘氨酸位点的间接调节。这些数据意味着NMDA与相关甘氨酸识别位点之间存在功能偶联,此外,还表明C-5和C-7竞争性NMDA拮抗剂与NMDA受体复合物存在不同的相互作用。